14.2 Health Promotion, Disease Prevention, and Wellness Coaching

14.2 Health Promotion, Disease Prevention, and Wellness Coaching

High-Yield Exam Focus: On the ANCC CMGT-BC examination, wellness promotion and disease prevention questions test the nurse case manager's ability to categorize interventions across the three epidemiological levels of prevention (Primary, Secondary, Tertiary), apply USPSTF Grade A and Grade B clinical screening recommendations (including precise age cutoffs, modalities, and high-risk qualifying criteria), navigate CDC/ACIP adult immunization schedules (particularly the age-50 pneumococcal threshold and PCV20/PCV21/PCV15 protocols, recombinant zoster Shingrix rules, and RSV indications), and operationalize Albert Bandura's Self-Efficacy Theory, the Transtheoretical Model (Stages of Change), and Motivational Interviewing (OARS) in professional wellness coaching.

---

Epidemiological Foundations: The Three Levels of Prevention

Contemporary healthcare systems are rapidly transitioning from reactive, downstream sickness treatment toward upstream wellness promotion, preventive screening, and proactive population health navigation. To optimize clinical outcomes, close quality care gaps, and maximize value-based purchasing benchmarks, nurse case managers must align clinical interventions with the natural history of disease across the three recognized epidemiological tiers of prevention.

┌────────────────────────────────────────────────────────────────────────┐
│                     THE NATURAL HISTORY OF DISEASE                     │
├─────────────────────┬──────────────────────────┬───────────────────────┤
│ PRE-PATHOGENESIS    │ PRECLINICAL / LATENT     │ CLINICAL / OVERT      │
│ (No Disease Present)│ (Asymptomatic Pathology) │ (Symptomatic Illness) │
├─────────────────────┼──────────────────────────┼───────────────────────┤
│  PRIMARY PREVENTION │   SECONDARY PREVENTION   │  TERTIARY PREVENTION  │
│  • Universal Imms   │   • Cancer Screenings    │  • Cardiac Rehab      │
│  • Smoking Avoidance│   • Blood Pressure Checks│  • Diabetic Foot Care │
│  • Diet / Exercise  │   • Fasting Lipid Panels │  • Post-Stroke Therapy│
│  • Fluoridation     │   • Pap Smears / Mammos  │  • Dialysis / Stents  │
└─────────────────────┴──────────────────────────┴───────────────────────┘

1. Primary Prevention

• Epidemiological Definition: Interventions executed during the pre-pathogenesis phase (before the biological onset of disease or tissue injury) that aim to prevent the occurrence of illness, injury, or disability by eliminating causal agents, reducing exposure to environmental hazards, and enhancing host resistance.
• Primary Mechanism: Health promotion, risk-factor eradication, and specific disease prophylaxis.
• Clinical & Case Management Examples:
  • Universal pediatric and adult immunizations (e.g., annual influenza, updated COVID-19, hepatitis B, HPV, recombinant zoster vaccine).
  • Comprehensive wellness education on balanced nutrition, physical fitness, and stress management for healthy individuals.
  • Youth smoking prevention and anti-vaping educational campaigns discouraging tobacco initiation.
  • Occupational health protocols: mandatory personal protective equipment (PPE), hearing protection, and ergonomic workstation evaluations.
  • Environmental and public health engineering: municipal water fluoridation to prevent dental caries, lead service line abatement, and fortification of enriched cereal grain products with folic acid to prevent fetal neural tube defects.

2. Secondary Prevention

• Epidemiological Definition: Interventions directed at the preclinical, latent, or early asymptomatic phase of disease to detect pathology at the earliest possible stage, enabling prompt clinical intervention to arrest disease progression, cure early malignancy, reduce disease prevalence, and prevent long-term morbidity.
• Primary Mechanism: Screening asymptomatic populations, proactive case-finding, and prompt diagnostic evaluation.
• Core Clinical Distinction: Screening tests do not establish a definitive pathological diagnosis; rather, they identify asymptomatic individuals with a high probability of occult disease who require diagnostic testing.
• Clinical & Case Management Examples:
  • Oncological screening: screening mammography, screening colonoscopy, fecal immunochemical testing (FIT), cervical cytology (Pap smear), and low-dose computed tomography (LDCT) for lung cancer.
  • Cardiovascular and metabolic screening: routine blood pressure screening at primary care encounters to detect asymptomatic hypertension; fasting lipid profiles to identify dyslipidemia; fasting plasma glucose or HbA1c screening for prediabetes.
  • Visual and sensory surveillance: annual dilated retinal examinations in patients with diabetes to detect asymptomatic diabetic retinopathy prior to irreversible visual impairment; total-body skin cancer visual surveillance.

3. Tertiary Prevention

• Epidemiological Definition: Interventions deployed during the overt clinical, symptomatic, or advanced phase of disease designed to manage established chronic conditions, minimize physical and psychological disability, restore optimal functional capacity, and prevent secondary clinical complications, disease deterioration, and avoidable readmissions.
• Primary Mechanism: Rehabilitation, multidisciplinary disease management, secondary complication prophylaxis, and palliative stabilization.
• Clinical & Case Management Examples:
  • Phase II and III multidisciplinary outpatient cardiac rehabilitation following an acute myocardial infarction or coronary artery bypass graft (CABG) surgery to restore aerobic capacity, improve endothelial function, and reduce cardiovascular mortality.
  • Outpatient pulmonary rehabilitation for symptomatic COPD patients to improve functional exercise tolerance and breathing efficiency.
  • Comprehensive daily diabetic foot self-inspections, professional podiatric toenail debridement, and specialized therapeutic diabetic orthotic footwear to prevent diabetic foot ulcers, osteomyelitis, and lower-extremity amputations.
  • Physical, occupational, and speech therapy following acute ischemic stroke to restore motor function, prevent aspiration pneumonia, and treat neurogenic dysphagia.
  • Guideline-directed medical therapy titration (e.g., beta-blockers, ACE inhibitors) for diagnosed heart failure to prevent acute pulmonary edema.

---

U.S. Preventive Services Task Force (USPSTF) Screening Framework

The U.S. Preventive Services Task Force (USPSTF) is an independent, volunteer panel of national experts in disease prevention and evidence-based medicine that issues rigorous, systematic recommendations for clinical preventive services in primary care settings.

USPSTF Recommendation Grades & Affordable Care Act (ACA) Mandates

High-Yield USPSTF Grade A and B Clinical Recommendations

┌────────────────────────────────────────────────────────────────────────┐
│               HIGH-YIELD USPSTF GRADE A & B SCREENING PROTOCOLS        │
├───────────────────┬────────────────────────────────────────────────────┤
│ Colorectal Cancer │ Ages 45–75: Routine screening for all adults (Gr.A)│
│ Breast Cancer     │ Ages 40–74: Biennial screening mammography (Gr. B) │
│ Cervical Cancer   │ Ages 21–65: Cytology q3y, hrHPV q5y (30-65) (Gr. A)│
│ Lung Cancer       │ Ages 50–80: Annual Low-Dose CT (20 pk-yr) (Gr. B)  │
│ Prediabetes / T2D │ Ages 35–70: Screen overweight/obese adults (Gr. B) │
│ Statin Prevention │ Ages 40–75: 1+ CVD risk factor & ASCVD ≥10% (Gr. B)│
│ AAA Ultrasound    │ Ages 65–75: One-time US in men who ever smoked (B) │
└───────────────────┴────────────────────────────────────────────────────┘

1. Colorectal Cancer (CRC) Screening

• Target Population & Age Range: All average-risk adults aged 45 to 75 years, but the grades differ by age band and the difference is testable: ages 50-75 carry a Grade A recommendation (high certainty of substantial net benefit), while ages 45-49 carry a Grade B (moderate net benefit) after the USPSTF lowered the starting age from 50 to 45. Both grades trigger zero cost-sharing under ACA Section 2713.
• Older Adults (76–85 years): Selectively screen based on the patient's overall health, prior screening history, and preferences (Grade C). Routine screening is not recommended for adults >85 years.
• Acceptable Screening Modalities & Intervals:
  • Direct Visualization Tests: Colonoscopy every 10 years, OR Computed Tomography (CT) Colonography every 5 years, OR Flexible Sigmoidoscopy every 5 years (or every 10 years if combined with annual FIT).
  • High-Sensitivity Stool-Based Tests: Annual Fecal Immunochemical Test (FIT), OR annual high-sensitivity guaiac-based Fecal Occult Blood Test (gFOBT), OR Stool DNA-FIT test (e.g., Cologuard) every 3 years.
• Case Management Workflow: If any non-colonoscopy screening test (e.g., FIT or Stool DNA) returns abnormal or positive, the case manager must immediately coordinate a timely follow-up diagnostic colonoscopy to evaluate for precancerous polyps or colorectal adenocarcinoma.

2. Breast Cancer Screening

• Target Population & Modality: All asymptomatic cisgender women and people assigned female at birth at average risk for breast cancer.
• Updated USPSTF Protocol: Biennial (every 2 years) screening mammography for women aged 40 to 74 years (Grade B recommendation; updated from the prior recommendation that started routine screening at age 50).

3. Cervical Cancer Screening

• Target Population: Asymptomatic women aged 21 to 65 years with a cervix, regardless of sexual history or HPV vaccination status (Grade A).
• Age-Stratified Strategy:
  • Ages 21 to 29 Years: Cervical cytology (Pap smear) alone every 3 years. (Do not screen with hrHPV testing alone or co-testing in this cohort due to high prevalence of transient, self-resolving HPV infections in younger individuals).
  • Ages 30 to 65 Years: Three equally valid clinical options: Cervical cytology alone every 3 years, OR high-risk human papillomavirus (hrHPV) testing alone every 5 years, OR co-testing (cytology combined with hrHPV) every 5 years.
• Discontinuation Criteria: Screening should be discontinued in women aged >65 years who have had adequate prior screening (3 consecutive negative cytology results or 2 consecutive negative hrHPV results within the past 10 years, with the most recent test within 5 years) and are not at high risk for cervical cancer. Women who have had a total hysterectomy with removal of the cervix for benign indications do not require screening.

4. Lung Cancer Screening

• Target Population & Modality: Annual screening with Low-Dose Computed Tomography (LDCT) for adults aged 50 to 80 years (Grade B).
• Eligibility Criteria: Individuals who have a ≥20 pack-year smoking history AND currently smoke or have quit within the past 15 years.
• Discontinuation Criteria: Discontinue screening once an individual has not smoked for 15 consecutive years, develops a health problem that substantially limits life expectancy, or is unable/unwilling to undergo curative lung surgery.

5. Prediabetes and Type 2 Diabetes Screening

• Target Population & Modality: Asymptomatic nonpregnant adults aged 35 to 70 years who are classified as overweight or obese (Body Mass Index [BMI] ≥25 kg/m², or ≥23 kg/m² in Asian Americans) (Grade B).
• Screening Tests: Fasting plasma glucose, 2-hour oral glucose tolerance test (OGTT), or glycated hemoglobin (HbA1c).
• Screening Interval: Every 3 years if test results are normal; annual surveillance if prediabetes is identified.

6. Statin Therapy for Primary CVD Prevention

• Target Population: Adults aged 40 to 75 years with no history of cardiovascular disease (CVD), who possess 1 or more CVD risk factors (dyslipidemia, diabetes, hypertension, or current smoking), and have a calculated 10-year atherosclerotic cardiovascular disease (ASCVD) risk of ≥10% (Grade B) or 7.5% to <10% (Grade C).
• Intervention: Initiate low- to moderate-intensity statin therapy (e.g., atorvastatin 10–20 mg or rosuvastatin 5–10 mg daily) to prevent first cardiovascular events.

7. Abdominal Aortic Aneurysm (AAA) Screening

• Target Population & Modality: One-time screening ultrasonography of the abdominal aorta (Grade B).
• Clinical Eligibility: Men aged 65 to 75 years who have ever smoked (defined epidemiologically as having smoked at least 100 cigarettes in their lifetime).
• Clinical Nuance: For men aged 65–75 who have never smoked, AAA screening is selectively offered (Grade C). Routine screening is not recommended in women who have never smoked (Grade D).

---

CDC / ACIP Adult Immunization Standards

The Advisory Committee on Immunization Practices (ACIP) of the Centers for Disease Control and Prevention (CDC) issues evidence-based adult vaccination schedules. Nurse case managers serve as crucial patient advocates to overcome vaccine hesitancy, assess immunization histories, and facilitate point-of-care vaccination during clinical transitions.

┌────────────────────────────────────────────────────────────────────────┐
│               ACIP ADULT IMMUNIZATION SCHEDULE HIGHLIGHTS              │
├───────────────────┬────────────────────────────────────────────────────┤
│ Influenza         │ Annual seasonal dose for ALL individuals ≥6 months │
│ COVID-19          │ Annual updated formulation for ALL ≥6 months       │
│ Pneumococcal      │ Age ≥50 (lowered from 65 by ACIP, Oct 2024) OR     │
│                   │ 19–49 with risk: single dose PCV20, PCV21, or     │
│                   │ PCV15 followed by PPSV23 ≥1 year later             │
│ Recombinant Zoster│ 2-dose series (0, 2–6 mos) for ALL adults ≥50      │
│ (Shingrix)        │ (regardless of prior shingles or Zostavax history!)│
│ RSV Vaccine       │ Single lifetime dose for ALL ≥75, or 60–74 at risk │
│ Tdap / Td         │ Tdap once, then Td/Tdap booster every 10 years;    │
│                   │ 1 dose Tdap during EVERY pregnancy (27–36 weeks)   │
└───────────────────┴────────────────────────────────────────────────────┘

Detailed Analysis of Core Adult Vaccines

1. Pneumococcal Conjugate Vaccination (PCV20 vs. PCV15 + PPSV23):

   • Target Population: All immunocompetent adults aged ≥65 years, AND adults aged 19 to 64 years with chronic risk conditions (chronic heart failure, chronic lung disease/COPD/asthma, diabetes mellitus, chronic kidney disease, chronic liver disease, alcoholism, cigarette smoking) or immunocompromising conditions (asplenia, HIV, leukemia, immunosuppressive therapy, cochlear implants, CSF leaks).
   • Age Threshold (updated): On October 23, 2024, ACIP voted to lower the routine age for pneumococcal vaccination from 65 to 50 years, and CDC adopted the recommendation. Adults aged 19-49 remain recommended for vaccination when they have qualifying risk conditions. Do not carry the old "age 65" cutoff into the exam.
   • Current ACIP Regimens: Pneumococcal-conjugate-naive adults should receive either:
     • A single dose of PCV20 (Prevnar 20) or PCV21 (Capvaxive, FDA-approved June 2024 for adults**)** alone, with no subsequent PPSV23 required, OR
     • A single dose of PCV15 (Vaxneuvance), followed at least 1 year later by a dose of PPSV23 (Pneumovax 23) (interval shortened to ≥8 weeks for immunocompromised individuals).
   • Immunological Distinction: Conjugate vaccines (PCV) couple pneumococcal capsular polysaccharides to a diphtheria carrier protein, stimulating T-cell-dependent immune memory that creates mucosal immunity and long-lasting anamnestic protection. Older polysaccharide vaccines (PPSV23) stimulate only T-cell-independent B-cell responses without generating immune memory.

2. Recombinant Zoster Vaccine (Shingrix; RZV):

   • Target Population: All immunocompetent adults aged ≥50 years, AND adults aged ≥19 years who are or will be immunocompromised.
   • Dosing Regimen: 2-dose intramuscular series, administered at 0 and 2 to 6 months.
   • Critical Exam Nuance: Shingrix must be administered regardless of whether the patient has a documented prior history of herpes zoster (shingles) and regardless of whether the patient previously received the older live attenuated zoster vaccine (Zostavax). Prior natural infection or live vaccination does not provide lifelong immunity, and Shingrix provides >90% sustained efficacy against herpes zoster and postherpetic neuralgia.

3. Respiratory Syncytial Virus (RSV) Vaccine:

   • Target Population: All adults aged ≥75 years, AND adults aged 60 to 74 years who are at increased risk of severe RSV disease (chronic cardiovascular disease, COPD/emphysema/asthma, CKD, diabetes, severe obesity [BMI ≥40], or residence in a nursing facility).
   • Regimen: A single lifetime dose administered in late summer or early autumn prior to the RSV viral season.

4. Seasonal Influenza & Updated COVID-19:

   • Target Population: Universal annual vaccination for all individuals aged ≥6 months without contraindications.
   • Older Adults (≥65 years): Preferentially administer higher-dose, recombinant, or adjuvanted inactivated influenza vaccines (e.g., Fluzone High-Dose, Flublok Recombinant, Fluad Adjuvanted) to overcome immunosenescence.

5. Tetanus, Diphtheria, Pertussis (Tdap / Td):

   • Target Population: All adults who have never received a dose of Tdap should receive 1 dose immediately, followed by a Td or Tdap booster every 10 years.
   • Antepartum Administration: Administer 1 dose of Tdap during every pregnancy, ideally between 27 and 36 weeks of gestation, regardless of the woman's prior vaccination history. Transplacental transfer of maternal IgG antibodies provides critical passive immunity shielding the infant from life-threatening pertussis during the first two months of life prior to primary infant immunization.

---

Wellness Coaching, Goal-Setting, and Behavioral Science

Clinical knowledge alone rarely translates into sustained patient behavior change. Registered nurse case managers utilize evidence-based behavioral psychology and wellness coaching frameworks to empower patients, activate self-advocacy, and build durable self-management habits.

Albert Bandura's Social Cognitive Theory & Self-Efficacy

Self-efficacy, conceptualized by psychologist Albert Bandura, refers to an individual's subjective belief in their personal ability to organize and execute the actions required to achieve specific performance attainments or manage health demands. In chronic disease management, self-efficacy is the strongest psychological predictor of medication adherence, dietary compliance, physical activity adoption, and symptom self-regulation.

┌────────────────────────────────────────────────────────────────────────┐
│                     BANDURA'S FOUR SOURCES OF SELF-EFFICACY            │
├──────────────────────────────────┬─────────────────────────────────────┤
│ 1. MASTERY EXPERIENCES           │ 2. VICARIOUS EXPERIENCES (MODELING) │
│    • Most powerful source        │    • Observing peers with similar   │
│    • Small, incremental successes│      conditions succeed             │
│    • Graded task achievement     │    • Peer support groups & mentors  │
├──────────────────────────────────┼─────────────────────────────────────┤
│ 3. VERBAL / SOCIAL PERSUASION    │ 4. PHYSIOLOGICAL & AFFECTIVE STATES │
│    • Credible, trustworthy       │    • Reinterpreting somatic signals │
│      encouragement from coach    │    • Stress reduction & relaxation  │
│    • Reframing setbacks as data  │    • Managing anxiety and fatigue   │
└──────────────────────────────────┴─────────────────────────────────────┘

The Four Sources Deconstructed in Case Management

1. Mastery Experiences (Enactive Mastery): Experiencing direct, personal success in performing a targeted behavior. This is the single most influential source of self-efficacy. Case managers build mastery by breaking complex, overwhelming health demands into small, graded, easily achievable steps (e.g., coaching a sedentary heart failure patient to walk for 5 minutes daily for one week, rather than demanding 30 minutes immediately). Success builds confidence, which cascades into larger behavior changes.
2. Vicarious Experiences (Social Modeling): Seeing people similar to oneself perform a behavior successfully. When a patient observes a peer with comparable physical limitations and social barriers successfully managing insulin injections or preparing low-sodium meals, their belief in their own capability increases. Case managers operationalize this through diabetic peer-support groups, patient mentoring programs, and sharing relatable patient narratives.
3. Verbal / Social Persuasion: Receiving credible, constructive encouragement from trusted healthcare professionals. Persuasion is most effective when it focuses on realistic capabilities rather than vague cheerleading (e.g., "Based on how consistently you recorded your blood pressure this past week, I know you have the organizational skills to track your morning weights accurately").
4. Physiological and Affective States: Somatic feedback (pain, fatigue, shortness of breath, anxiety) is frequently misinterpreted by patients as physical vulnerability or impending failure. Case managers help patients manage stress, teach relaxation techniques, and reframe physiological symptoms (e.g., explaining that mild muscle fatigue after cardiac rehab walking is normal muscular conditioning rather than a sign of recurrent heart damage).

Integration with the Transtheoretical Model (Stages of Change)

Developed by Prochaska and DiClemente, the Transtheoretical Model (TTM) posits that individuals move through six distinct stages of readiness when modifying health behaviors. Case managers tailor coaching strategies to the patient's current stage:

┌────────────────────────────────────────────────────────────────────────┐
│                TRANSTHEORETICAL MODEL (STAGES OF CHANGE)               │
├───────────────────┬────────────────────────────────┬───────────────────┤
│ STAGE OF CHANGE   │ PATIENT MINDSET & READINESS    │ CASE MANAGER ROLE │
├───────────────────┼────────────────────────────────┼───────────────────┤
│ Precontemplation  │ • "I don't have a problem"     │ • Avoid lecturing │
│                   │ • No intention to change in    │ • Raise awareness │
│                   │   next 6 months                │ • Explore values  │
├───────────────────┼────────────────────────────────┼───────────────────┤
│ Contemplation     │ • "I know I should, but..."    │ • Explore ambiv-  │
│                   │ • Considering change in next   │   alence (pros/   │
│                   │   6 months; deeply ambivalent  │   cons of change) │
├───────────────────┼────────────────────────────────┼───────────────────┤
│ Preparation       │ • "I'm ready to try next week" │ • Co-create SMART │
│                   │ • Intends to act within 30 days│   goals & plan    │
│                   │ • Taking small initial steps   │ • Identify allies │
├───────────────────┼────────────────────────────────┼───────────────────┤
│ Action            │ • "I am doing it right now"    │ • Reinforce self- │
│                   │ • Practicing new behavior for  │   efficacy        │
│                   │   less than 6 months           │ • Overcome barriers│
├───────────────────┼────────────────────────────────┼───────────────────┤
│ Maintenance       │ • "This is part of my life"    │ • Relapse preven- │
│                   │ • Sustained behavior change    │   tion strategies │
│                   │   for >6 months                │ • Generalize habits│
├───────────────────┼────────────────────────────────┼───────────────────┤
│ Relapse           │ • Setback to earlier stage     │ • Reframe as learn-│
│ (Recycle)         │ • Guilt, frustration, defeat   │   ing experience  │
└───────────────────┴────────────────────────────────┴───────────────────┘

Motivational Interviewing (MI) in Wellness Coaching

Motivational Interviewing (MI), developed by Miller and Rollnick, is a collaborative, goal-oriented communication style designed to strengthen a person's own motivation and commitment to change by exploring and resolving ambivalence.

• The Spirit of MI (PACE): Partnership (collaborative alliance, not expert-to-patient lecture), Acceptance (unconditional positive regard and respecting autonomy), Compassion (acting in the patient's best interest), and Evocation (drawing out the patient's own reasons and internal motivation for change, rather than imposing external advice).
• Core MI Micro-Skills (OARS):
  • Open-Ended Questions: Inviting the patient to explore their own perspectives (e.g., "What changes would you like to see in your energy levels over the next three months?").
  • Affirmations: Acknowledging the patient's inherent strengths, efforts, and values (e.g., "Your persistence in finding time to walk despite your demanding work schedule shows real dedication to your family's future").
  • Reflective Listening: Mirroring back the emotional and cognitive content of the patient's speech to demonstrate deep empathy and clarify meaning (e.g., "You're worried that taking insulin means your diabetes has gotten worse, but you also want to protect your vision").
  • Summarizing: Pulling together key points, ambivalence, and self-expressed reasons for change at transitions during the encounter.
• Eliciting Change Talk (DARN-CAT): The case manager listens for and amplifies Change Talk (speech favoring change), distinguishing preparatory language (Desire, Ability, Reasons, Need) from mobilizing commitment language (Commitment, Activation, Taking steps).

Structured Goal-Setting & The SMART Protocol

Effective wellness coaching requires translating broad, vague aspirations into concrete behavioral action plans using the SMART framework:

• Specific: Clear, precise definition of who, what, where, and when (e.g., "Walk around the neighborhood block" instead of "Exercise more").
• Measurable: Quantifiable criteria to track progress (e.g., "For 15 minutes, 4 days per week").
• Achievable: Realistic given current physical capabilities, time constraints, and resources.
• Relevant: Directly aligned with the patient's personal values and health objectives (e.g., "To build stamina to play with my grandchildren").
• Time-Bound: Established timeframe and designated start/review date (e.g., "Starting Monday morning for the next two weeks").

The 0-to-10 Confidence Scaling Protocol

After a SMART goal is formulated, the nurse case manager administers a Confidence Scale:

"On a scale of 0 to 10, where 0 means not confident at all and 10 means extremely confident, how confident are you that you can achieve this specific goal this week?"

• The Rule of 7 Threshold: If the patient rates their confidence below 7 out of 10, the goal is too ambitious and carries a high risk of failure, which would destroy self-efficacy. The case manager immediately collaborates with the patient to downscale or modify the goal (e.g., reducing walking frequency from 4 days to 2 days) until the patient rates their confidence as a 7 or higher. Achieving this smaller goal provides an initial mastery experience.

Empowering Patient Accountability & Managing Lapses

• Self-Monitoring Tools: Accountability is reinforced by active patient engagement with self-monitoring instruments: food diaries, physical activity step counters, blood glucose logs, and mobile health apps.
• Reframing Lapses as Learning Opportunities: In behavioral science, a lapse (a temporary slip or single missed target) is distinguished from a relapse (a complete abandonment of the new behavior). Case managers teach patients to anticipate high-risk situations (social holidays, acute stress, inclement weather) and reframe slips without guilt or shame: "What triggered that missed walk, and what can we learn from it to adjust our plan for next week?"

---

Clinical Case Scenario: Multidimensional Preventive Care & Wellness Coaching

Clinical History & Presentation

A 53-year-old female presents to an ambulatory case management clinic for an annual preventive assessment. Medical history is notable for mild hypertension and obesity (BMI 31.4 kg/m²). She currently smokes 1 pack of cigarettes daily and has done so for 22 years (22 pack-year smoking history). Her family history is significant for her mother developing breast cancer at age 62 and her father developing colon cancer at age 70.

Preventive Care Gap Assessment

The nurse case manager audits the patient's electronic health record against USPSTF Grade A/B screening standards and ACIP adult immunization guidelines:

1. Colorectal Cancer Screening: Patient has never undergone screening. At age 53, she is overdue for routine screening (Grade A applies from ages 50-75; Grade B covers ages 45-49).
2. Breast Cancer Screening: Last screening mammogram was 3 years ago (Grade B: biennial screening for women aged 40–74).
3. Cervical Cancer Screening: Last cervical cytology (Pap smear) was 4 years ago. At age 53, she is eligible for co-testing every 5 years or cytology alone every 3 years (Grade A).
4. Lung Cancer Screening: Patient meets all criteria for annual low-dose CT (LDCT) lung cancer screening: age 50–80 (she is 53), ≥20 pack-year smoking history (she has 22 pack-years), and currently smokes (Grade B).
5. Prediabetes/Diabetes Screening: At age 53 with a BMI of 31.4 kg/m², she meets criteria for diabetes screening with fasting glucose or HbA1c (Grade B: ages 35–70 with overweight/obesity).
6. Immunizations: State registry reveals she received an annual flu shot 11 months ago, but has never received the recombinant zoster series (Shingrix), has not received an updated COVID-19 vaccine, and her last tetanus booster was 14 years ago.

Case Manager Operational Action & Wellness Coaching Intervention

• Coordinating Clinical Preventive Services: The case manager orders an annual low-dose CT (LDCT) scan for lung cancer screening, schedules a screening colonoscopy (explaining that stool FIT is also an option, but colonoscopy provides direct visualization), orders a biennial screening mammogram, and schedules an in-clinic cervical cytology collection. The case manager administers a Tdap booster and the first dose of the recombinant zoster vaccine (Shingrix), scheduling the second dose for 3 months later.
• Applying Behavioral Coaching for Smoking Cessation:
  • Assessing Stage: The patient states, "I know smoking is terrible for me, and I cough every morning, but it's the only way I cope with job stress." The case manager recognizes the Contemplation stage.
  • Motivational Interviewing (Exploring Ambivalence): The case manager uses reflective listening: "Smoking feels like your only stress relief right now, but your morning cough is a reminder of how it's affecting your lungs." The patient nods and expresses desire to quit before her first grandchild is born.
  • Confidence Scaling & SMART Goal: The case manager asks the patient to identify one small step. The patient proposes: "Instead of smoking on my drive home from work, I will chew sugar-free cinnamon gum and listen to a podcast, starting Monday." The case manager checks confidence: "On a scale of 0 to 10, how confident are you?" The patient responds: "An 8!" Because the score is ≥7, the goal is finalized.
  • Outcome: Over the next 6 months, the patient successfully quits smoking with varenicline support, completes all cancer screenings (revealing a benign tubular adenoma removed during colonoscopy), and achieves full Shingrix vaccination.

---

Common Exam Traps & High-Yield Takeaways

• Exam Trap 1: Confusing Disease Screening with Primary Prevention. Always remember: screening tests (mammography, colonoscopy, low-dose CT, blood pressure checks, Pap smears) detect preclinical, asymptomatic disease and are strictly Secondary prevention. Interventions that stop disease before biological pathogenesis begins (vaccines, diet/exercise counseling, smoking prevention, fluoride) represent Primary prevention.
• Exam Trap 2: Mammography Starting Age Guidelines. Do not select age 50 as the starting age for routine screening mammography. Current USPSTF guidelines recommend biennial screening mammography beginning at age 40 (Grade B) through age 74.
• Exam Trap 3: Lung Cancer Screening Eligibility Prerequisites. Do not order lung cancer screening simply because a patient is older than 50 or because a patient smokes. The patient must satisfy all three criteria: age 50 to 80 years, a smoking history of at least 20 pack-years, AND currently smoke or have quit within the past 15 years.
• Exam Trap 4: AAA Screening Demographic Restrictions. A one-time abdominal aortic ultrasound is recommended specifically for men aged 65 to 75 who have ever smoked (≥100 lifetime cigarettes). It is not routinely recommended for women or for men who have never smoked.
• Exam Trap 5: Shingrix Administration in Patients with Prior Shingles. Exam questions frequently present an older adult who had shingles in the past or received the older Zostavax vaccine. The correct action is always to administer the 2-dose recombinant zoster series (Shingrix); prior herpes zoster does not convey permanent immunity, and Shingrix has superior, durable efficacy.
• Exam Trap 6: Paternalistic Goal Setting in Wellness Coaching. Never select an answer where the case manager unilaterally assigns a diet or exercise regimen to a patient. In evidence-based wellness coaching, goals must be patient-directed, collaborative, formulated as SMART goals, and evaluated with confidence scaling (requiring a score of ≥7/10).